Procaps Group (PROC) Competitors $2.51 +0.07 (+2.87%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends PROC vs. RCUS, NRIX, KNSA, IMCR, OCUL, MESO, NTLA, TVTX, PRAX, and ARVNShould you be buying Procaps Group stock or one of its competitors? The main competitors of Procaps Group include Arcus Biosciences (RCUS), Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Immunocore (IMCR), Ocular Therapeutix (OCUL), Mesoblast (MESO), Intellia Therapeutics (NTLA), Travere Therapeutics (TVTX), Praxis Precision Medicines (PRAX), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry. Procaps Group vs. Arcus Biosciences Nurix Therapeutics Kiniksa Pharmaceuticals Immunocore Ocular Therapeutix Mesoblast Intellia Therapeutics Travere Therapeutics Praxis Precision Medicines Arvinas Procaps Group (NASDAQ:PROC) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking. Does the MarketBeat Community favor PROC or RCUS? Arcus Biosciences received 191 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 65.54% of users gave Arcus Biosciences an outperform vote while only 37.50% of users gave Procaps Group an outperform vote. CompanyUnderperformOutperformProcaps GroupOutperform Votes337.50% Underperform Votes562.50% Arcus BiosciencesOutperform Votes19465.54% Underperform Votes10234.46% Which has more volatility & risk, PROC or RCUS? Procaps Group has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Do analysts rate PROC or RCUS? Arcus Biosciences has a consensus price target of $34.00, suggesting a potential upside of 119.35%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than Procaps Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Procaps Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor PROC or RCUS? In the previous week, Arcus Biosciences had 1 more articles in the media than Procaps Group. MarketBeat recorded 5 mentions for Arcus Biosciences and 4 mentions for Procaps Group. Arcus Biosciences' average media sentiment score of 0.78 beat Procaps Group's score of 0.17 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Procaps Group 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, PROC or RCUS? Procaps Group has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Procaps Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProcaps Group$414.10M0.68$42.54M$0.524.83Arcus Biosciences$263M5.39-$307M-$3.15-4.92 Do insiders and institutionals hold more shares of PROC or RCUS? 92.9% of Arcus Biosciences shares are owned by institutional investors. 19.9% of Procaps Group shares are owned by insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is PROC or RCUS more profitable? Procaps Group has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. Procaps Group's return on equity of 0.00% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Procaps GroupN/A N/A N/A Arcus Biosciences -102.66%-45.59%-22.38% SummaryArcus Biosciences beats Procaps Group on 11 of the 19 factors compared between the two stocks. Ad ProsperityPubCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get Procaps Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PROC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROC vs. The Competition Export to ExcelMetricProcaps GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$283.18M$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E Ratio4.8310.5089.8217.18Price / Sales0.68195.801,116.21116.95Price / Cash4.2957.1642.8937.86Price / Book-125.505.094.784.78Net Income$42.54M$151.83M$120.23M$225.60M7 Day Performance4.15%-2.13%-1.92%-1.23%1 Month Performance126.13%-3.10%11.49%3.36%1 Year Performance-24.17%11.54%30.57%16.60% Procaps Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROCProcaps Group0.8826 of 5 stars$2.51+2.9%N/A-20.3%$283.18M$414.10M4.835,500News CoverageHigh Trading VolumeRCUSArcus Biosciences2.6476 of 5 stars$16.31+1.4%$34.00+108.5%-9.3%$1.49B$117M-5.11500News CoverageNRIXNurix Therapeutics2.5066 of 5 stars$20.98+3.5%$30.35+44.7%+101.7%$1.49B$56.42M-6.97300News CoverageKNSAKiniksa Pharmaceuticals2.5299 of 5 stars$20.22+0.1%$36.60+81.0%+15.4%$1.46B$384.10M-147.36220Positive NewsIMCRImmunocore2.4974 of 5 stars$28.73-0.6%$65.64+128.5%-51.4%$1.44B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.6452 of 5 stars$9.04+4.0%$16.71+84.9%+116.8%$1.42B$58.44M0.00267Positive NewsMESOMesoblast1.0377 of 5 stars$12.09+2.8%$11.50-4.9%+590.1%$1.38B$5.90M0.0080Analyst ForecastOptions VolumeNews CoveragePositive NewsNTLAIntellia Therapeutics4.2166 of 5 stars$13.50+4.7%$54.94+306.9%-58.9%$1.37B$36.28M-2.37600TVTXTravere Therapeutics2.7678 of 5 stars$17.60+1.6%$22.62+28.5%+106.0%$1.37B$145.24M-3.81460Positive NewsPRAXPraxis Precision Medicines2.4017 of 5 stars$71.55+2.0%$146.33+104.5%+323.0%$1.33B$2.45M-7.06110Gap DownHigh Trading VolumeARVNArvinas2.031 of 5 stars$18.95-2.8%$63.50+235.1%-49.3%$1.30B$78.50M-4.18445 Related Companies and Tools Related Companies Arcus Biosciences Alternatives Nurix Therapeutics Alternatives Kiniksa Pharmaceuticals Alternatives Immunocore Alternatives Ocular Therapeutix Alternatives Mesoblast Alternatives Intellia Therapeutics Alternatives Travere Therapeutics Alternatives Praxis Precision Medicines Alternatives Arvinas Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PROC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Procaps Group S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Procaps Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
